ECSP088799A - Composiciones que comprenden células madre embrionarias humanas y sus derivados, métodos de uso y métodos de preparación - Google Patents

Composiciones que comprenden células madre embrionarias humanas y sus derivados, métodos de uso y métodos de preparación

Info

Publication number
ECSP088799A
ECSP088799A EC2008008799A ECSP088799A ECSP088799A EC SP088799 A ECSP088799 A EC SP088799A EC 2008008799 A EC2008008799 A EC 2008008799A EC SP088799 A ECSP088799 A EC SP088799A EC SP088799 A ECSP088799 A EC SP088799A
Authority
EC
Ecuador
Prior art keywords
factor
methods
derivatives
relates
stem cells
Prior art date
Application number
EC2008008799A
Other languages
English (en)
Inventor
Geeta Shroff
Original Assignee
Geeta Shroff
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Geeta Shroff filed Critical Geeta Shroff
Publication of ECSP088799A publication Critical patent/ECSP088799A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/31—Pituitary sex hormones, e.g. follicle-stimulating hormone [FSH], luteinising hormone [LH]; Chorionic gonadotropins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/39—Steroid hormones
    • C12N2501/392—Sexual steroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Reproductive Health (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Neurology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica que comprende preparaciones de células madre embrionarias humanas (hES) y sus derivados, y a procedimientos para su transplante en el cuerpo humano, en donde el transplante da como resultado la inversión clínica de síntomas, cura, estabilización o detención de degeneración de una amplia variedad de condiciones, enfermedades y trastornos médicos actualmente incurable y terminales. La invención se refiere además a procesos nuevos para preparar líneas de células madre nuevas que están libres de productos animales, células alimentadoras, factores de crecimiento, factor inhibidor de leucemia, combinaciones de minerales complementarios, suplementos de aminoácidos, suplementos vitamínicos, factor de crecimiento fibrolastos, factor Steel asociado a membrana, factor Steelsoluble y medios acondicionados. Esta invención se refiere además al asilamiento, cultivo, mantenimiento, expansión, diferenciación, almacenamiento y conservación de estas células madre.
EC2008008799A 2006-03-07 2008-10-07 Composiciones que comprenden células madre embrionarias humanas y sus derivados, métodos de uso y métodos de preparación ECSP088799A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN582DE2006 2006-03-07
IN1500DE2006 2006-06-26
US84435006P 2006-09-14 2006-09-14

Publications (1)

Publication Number Publication Date
ECSP088799A true ECSP088799A (es) 2008-12-30

Family

ID=54150153

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008799A ECSP088799A (es) 2006-03-07 2008-10-07 Composiciones que comprenden células madre embrionarias humanas y sus derivados, métodos de uso y métodos de preparación

Country Status (23)

Country Link
US (9) US10545135B2 (es)
EP (11) EP2422800A3 (es)
JP (2) JP5649786B2 (es)
KR (2) KR101505382B1 (es)
CN (2) CN103893211A (es)
AP (1) AP2949A (es)
AU (1) AU2007257594B2 (es)
BR (1) BRPI0708576A2 (es)
CA (1) CA2644922C (es)
CR (1) CR10345A (es)
CU (1) CU20080161A7 (es)
DK (1) DK1993575T3 (es)
EA (1) EA027648B9 (es)
EC (1) ECSP088799A (es)
GE (1) GEP20135796B (es)
IL (1) IL193702A (es)
MA (1) MA30323B1 (es)
MX (1) MX347303B (es)
MY (1) MY154677A (es)
NO (1) NO20084181L (es)
NZ (2) NZ571127A (es)
PH (1) PH12014501028A1 (es)
WO (1) WO2007141657A2 (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2422800A3 (en) 2006-03-07 2013-03-06 Geeta Shroff Compositions comprising human embryonic stem cells and their derivatives, methods of use, and methods of preparation
WO2008132722A1 (en) 2007-04-26 2008-11-06 Ramot At Tel-Aviv University Ltd. Pluripotent autologous stem cells from oral mucosa and methods of use
EP2164505B1 (en) * 2007-05-28 2014-09-17 Monash University Treatment of chronic lung disease
US20090291061A1 (en) * 2008-05-21 2009-11-26 Riordan Neil H Stem cell therapy for blood vessel degeneration
EP2296672B1 (en) * 2008-06-11 2015-09-16 Fresenius Medical Care Deutschland GmbH Conditioned medium of liver progenitor cells
US20100010087A1 (en) * 2008-07-10 2010-01-14 Hong John J Methods for Inducing Stem Cell Migration and Specialization with EC-18
CN105349517B (zh) * 2008-11-14 2021-05-04 维赛特公司 源于人多能干细胞的胰腺细胞的包封
GB201111244D0 (en) * 2011-06-30 2011-08-17 Konink Nl Akademie Van Wetenschappen Knaw Culture media for stem cells
US8377432B2 (en) * 2009-09-02 2013-02-19 Khay-Yong Saw Method and composition for neochondrogenesis
WO2011028880A2 (en) 2009-09-04 2011-03-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for enhancing genome stability and telomere elongation in embryonic stem cells
WO2011047345A2 (en) * 2009-10-15 2011-04-21 Tai June Yoo Methods of treating diseases of conditions using mesenchymal stem cells
WO2011070974A1 (ja) * 2009-12-07 2011-06-16 国立大学法人名古屋大学 脂肪組織由来間葉系幹細胞を含有する、前立腺癌治療用細胞製剤
AU2011237743A1 (en) * 2010-04-08 2012-11-01 Anthrogenesis Corporation Treatment of sarcoidosis using placental stem cells
WO2011145110A1 (en) 2010-05-15 2011-11-24 Subhadra Dravida A novel cord blood plasma nutrient formulation and a method for the preparation thereof
US9724367B2 (en) * 2010-11-10 2017-08-08 Regenmed (Cayman) Ltd. Injectable formulations for organ augmentation
FR2986537B1 (fr) * 2012-02-07 2014-03-28 Oreal Procede d'evaluation d'actif(s) apte(s) a preserver la fonctionnalite des cellules souches epitheliales
US20150079047A1 (en) * 2012-04-16 2015-03-19 The Regents Of The University Of California Ocular therapeutics using embryonic stem cell microvesicles
WO2014089121A2 (en) * 2012-12-03 2014-06-12 Thomas Ichim Retrograde delivery of cells and nucleic acids for treatment of cardiovascular diseases
US9265458B2 (en) 2012-12-04 2016-02-23 Sync-Think, Inc. Application of smooth pursuit cognitive testing paradigms to clinical drug development
WO2014116786A1 (en) * 2013-01-25 2014-07-31 Zietchick Research Institute,Llc Use of human chorionic gonadotropin to treat cerebral palsy and/or its co-morbidities
CN103961373A (zh) * 2013-02-04 2014-08-06 西比曼生物科技（上海）有限公司 异体间质血管层细胞和异体间充质祖细胞在预防或治疗骨性关节炎中的应用
US9380976B2 (en) 2013-03-11 2016-07-05 Sync-Think, Inc. Optical neuroinformatics
ITMI20130513A1 (it) * 2013-04-05 2014-10-06 Euroclone S P A Metodo diagnostico per patologie autoimmuni del fegato
AU2015261380B2 (en) 2014-05-16 2021-04-15 Koninklijke Nederlandse Akademie Van Wetenschappen Improved culture method for organoids
KR101686315B1 (ko) 2015-01-09 2016-12-13 이화여자대학교 산학협력단 편도 유래 중간엽 줄기세포로부터 슈반 세포의 분화 방법
KR20160109356A (ko) 2015-03-11 2016-09-21 이화여자대학교 산학협력단 자가 면역 질환 예방 또는 치료용 조성물
KR20160109358A (ko) 2015-03-11 2016-09-21 이화여자대학교 산학협력단 면역 질환 예방 또는 치료용 조성물
KR102036029B1 (ko) 2015-03-11 2019-10-24 이화여자대학교 산학협력단 골수 부전 예방 또는 치료용 조성물
KR101885122B1 (ko) 2015-03-26 2018-09-11 이화여자대학교 산학협력단 분화촉진 및 지속형 스페로이드 형태의 편도 유래 줄기세포의 배양 방법
KR102358878B1 (ko) 2015-06-01 2022-02-08 메모리얼 슬로안 케터링 캔서 센터 중간뇌 도파민(mda) 뉴런의 시험관내 분화 방법
KR20180105236A (ko) 2016-02-05 2018-09-27 메모리얼 슬로안-케터링 캔서 센터 줄기 세포-유래 외배엽 계통 전구체의 분화 방법
CN105749254A (zh) * 2016-02-28 2016-07-13 深圳爱生再生医学科技有限公司 用于治疗血管性痴呆的干细胞制剂及其制备方法和应用
GB201603569D0 (en) 2016-03-01 2016-04-13 Koninklijke Nederlandse Akademie Van Wetenschappen Improved differentiation method
EP3464567A4 (en) 2016-05-27 2020-01-08 Memorial Sloan Kettering Cancer Center METHODS FOR DIFFERENTIATION OF STEM CELL-DERIVED PROPERTIES
US20180242590A1 (en) * 2016-09-23 2018-08-30 Peter Friedman Compositions and methods for treating citrus plants infected with bacteria and for promoting general agricultural health
CN106177918A (zh) * 2016-09-30 2016-12-07 广州赛莱拉干细胞科技股份有限公司 一种间充质干细胞注射液及其制备方法和应用
SG11201907030VA (en) * 2017-01-31 2019-08-27 Univ Osaka Method for controlling differentiation of pluripotent stem cells
US11590175B2 (en) 2017-08-23 2023-02-28 Merakris Therapeutics Llc Compositions containing amniotic components and methods for preparation and use thereof
KR102130493B1 (ko) 2018-07-11 2020-07-06 이화여자대학교 산학협력단 건선 예방 또는 치료용 조성물
KR102089476B1 (ko) 2018-07-11 2020-03-16 이화여자대학교 산학협력단 피부 염증 질환 예방 또는 치료용 조성물
KR20190120141A (ko) 2019-10-16 2019-10-23 이화여자대학교 산학협력단 골수 부전 예방 또는 치료용 조성물
KR20210119766A (ko) * 2020-03-25 2021-10-06 서울대학교병원 인간 배아줄기세포 유래 중간엽 줄기세포를 포함하는 망막색소변성의 예방 또는 치료용 약학적 조성물
EP4323505A1 (en) 2021-04-16 2024-02-21 Brainxell, Inc. Methods of making, expanding and purifying midbrain dopaminergic progenitor cells
CN113116933A (zh) * 2021-04-26 2021-07-16 河北医科大学第四医院 一种防治糖尿病足的干细胞组合物及其应用
CN114600872A (zh) 2022-04-13 2022-06-10 西安北光医学生物技术有限公司 一种细胞、组织或器官的抗损伤保存的方法及保存系统

Family Cites Families (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744347A (en) 1987-01-16 1998-04-28 Ohio University Edison Biotechnology Institute Yolk sac stem cells and their uses
WO1990001541A1 (en) 1988-08-04 1990-02-22 Amrad Corporation Limited In vitro propagation of embryonic stem cells
US5256560A (en) 1988-10-07 1993-10-26 University Of Saskatchewan Primitive cell colony stimulating factors and lymphohematopoietic progenitor cells
US5411883A (en) 1989-12-26 1995-05-02 Somatix Therapy Corporation Proliferated neuron progenitor cell product and process
US5061620A (en) 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
US5840580A (en) 1990-05-01 1998-11-24 Becton Dickinson And Company Phenotypic characterization of the hematopoietic stem cell
US5622853A (en) 1990-05-01 1997-04-22 Becton Dickinson And Company T lymphocyte precursor
EP0475292B1 (en) 1990-09-10 1999-06-30 Takeda Chemical Industries, Ltd. Human luteinizing hormone-human chorionic gonadotropin receptor (Human LH/hCG receptor)
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US5851832A (en) 1991-07-08 1998-12-22 Neurospheres, Ltd. In vitro growth and proliferation of multipotent neural stem cells and their progeny
US6410320B1 (en) 1992-03-02 2002-06-25 The University Of Michigan Method and compositions for isolation and growth of kidney tubule stem cells, in vitro kidney tubulogenesis and ex vivo construction of renal tubules
JPH06508528A (ja) 1992-03-23 1994-09-29 ネクセル　セラピューティクス　インコーポレーテッド インビトロ由来ヒト好中球前駆体細胞
WO1994000484A1 (en) 1992-06-22 1994-01-06 Young Henry E Scar inhibitory factor and use thereof
US5589376A (en) 1992-07-27 1996-12-31 California Institute Of Technology Mammalian neural crest stem cells
US5453357A (en) 1992-10-08 1995-09-26 Vanderbilt University Pluripotential embryonic stem cells and methods of making same
US5690926A (en) 1992-10-08 1997-11-25 Vanderbilt University Pluripotential embryonic cells and methods of making same
EP0669974A1 (en) 1992-11-16 1995-09-06 Rhone-Poulenc Rorer Pharmaceuticals Inc. Pluripotential quiescent stem cell population
DE4240635C2 (de) 1992-12-03 1997-07-10 Lothar Prof Dr Kanz Vermehrung hämatopoetischer Vorläuferzellen ex vivo sowieZusammensetzungen hämatopoetischer Wachstumsfaktoren
CA2170357A1 (en) 1993-08-25 1995-03-02 David Digiusto Method for producing a highly enriched population of hematopoietic stem cells
US5453457A (en) 1993-11-12 1995-09-26 Bayer Corporation Gamma-radiation-resistant polycarbonate composition
US5972627A (en) 1994-06-15 1999-10-26 Systemix, Inc. Method of purifying a population of cells enriched for dendritic and/or lymphoid progenitors and populations of cells obtained thereby
US5650317A (en) 1994-09-16 1997-07-22 Michigan State University Human breast epithelial cell type with stem cell and luminal epithelial cell characteristics
US5677136A (en) 1994-11-14 1997-10-14 Systemix, Inc. Methods of obtaining compositions enriched for hematopoietic stem cells, compositions derived therefrom and methods of use thereof
US5874301A (en) 1994-11-21 1999-02-23 National Jewish Center For Immunology And Respiratory Medicine Embryonic cell populations and methods to isolate such populations
US5914268A (en) 1994-11-21 1999-06-22 National Jewish Center For Immunology & Respiratory Medicine Embryonic cell populations and methods to isolate such populations
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
US5821108A (en) 1995-04-07 1998-10-13 The Board Of Trustees Of The Leland Stanford Junior University Enrichment for a thymocyte subset having progenitor cell activity using c-kit as a selection marker
US5876956A (en) 1995-05-15 1999-03-02 Johns Hopkins University School Of Medicine Methods for identification or purification of cells containing an enzymatic intracellular marker
US5908782A (en) 1995-06-05 1999-06-01 Osiris Therapeutics, Inc. Chemically defined medium for human mesenchymal stem cells
US6517872B1 (en) 1995-06-12 2003-02-11 Yeda Research And Development Co., Ltd. FGFR3 as a marker for mesenchymal skeletal progenitor cells
US5753505A (en) 1995-07-06 1998-05-19 Emory University Neuronal progenitor cells and uses thereof
GB9514816D0 (en) 1995-07-19 1995-09-20 Ucli Ltd Substances and their medical use
US5858782A (en) 1995-11-13 1999-01-12 Regents Of The University Of Michigan Functional human hematopoietic cells
US5997871A (en) 1996-06-24 1999-12-07 University Of Maryland Biotechnology Insitute Treatment and prevention of cancer by administration of derivatives of human chorionic gonadotropin
US6969608B1 (en) 1996-08-26 2005-11-29 Mcgill University Pharmaceuticals containing multipotential precursor cells from tissues containing sensory receptors
US6890724B2 (en) 1996-09-06 2005-05-10 California Institute Of Technology Methods and compositions for neural progenitor cells
US6028064A (en) 1996-09-13 2000-02-22 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of progestin products
CA2216439A1 (en) 1996-09-25 1998-03-25 Derek Van Der Kooy Pharmaceuticals containing retinal stem cells
AU5734998A (en) 1997-01-10 1998-08-03 Life Technologies, Inc. Embryonic stem cell serum replacement
US6090622A (en) 1997-03-31 2000-07-18 The Johns Hopkins School Of Medicine Human embryonic pluripotent germ cells
US6331406B1 (en) 1997-03-31 2001-12-18 The John Hopkins University School Of Medicine Human enbryonic germ cell and methods of use
US6583109B1 (en) 1997-06-24 2003-06-24 Robert C. Gallo Therapeutic polypeptides from β-hCG and derivatives
US6734015B1 (en) 1997-07-04 2004-05-11 University Of Utah Research Foundation Isolation of lineage-restricted neuronal precursors
US6908763B1 (en) 1997-08-22 2005-06-21 The Board Of Trustees Of The Leland Stanford Junior University Mammalian common lymphoid progenitor cell
US5968829A (en) 1997-09-05 1999-10-19 Cytotherapeutics, Inc. Human CNS neural stem cells
US6245757B1 (en) 1997-10-03 2001-06-12 Research Corporation Technologies, Inc. Use of progestins to treat ischemic event
JP3880795B2 (ja) 1997-10-23 2007-02-14 ジェロン・コーポレーション フィーダー細胞を含まない培養物中で、霊長類由来始原幹細胞を増殖させるための方法
CA2313250A1 (en) 1997-12-04 1999-06-10 Duke University Methods of isolating and using cd7+cd34-lin-hematopoietic cells
EP1060242A4 (en) 1998-01-23 2003-09-17 Imclone Systems Inc PURIFIED POPULATIONS OF STEM CELLS
AUPP244498A0 (en) * 1998-03-18 1998-04-09 Medvet Science Pty. Ltd. Keratinocyte stem cells
US6812027B2 (en) 1998-03-25 2004-11-02 Cornell Research Foundation, Inc. Discovery, localization, harvest, and propagation of an FGF2 and BDNF-responsive population of neural and neuronal progenitor cells in the adult human forebrain
US6835567B1 (en) 1998-04-14 2004-12-28 Signal Pharmaceuticals, Inc. PNS cell lines and methods of use therefor
DK1082410T3 (da) 1998-05-29 2007-11-26 Osiris Therapeutics Inc Humane CD45 - og/eller fibroblast mesenchymale stamceller
US6129911A (en) 1998-07-10 2000-10-10 Rhode Island Hospital, A Lifespan Partner Liver stem cell
US6913925B1 (en) 1998-08-12 2005-07-05 Signal Pharmaceuticals Llc Human mesencephalon cell lines and methods of use therefor
DE19837438A1 (de) 1998-08-18 2000-02-24 Biotechnolog Forschung Gmbh Rekombinante Humanzelle für Knochen- und Knorpelzellbildung
US6767737B1 (en) 1998-08-31 2004-07-27 New York University Stem cells bearing an FGF receptor on the cell surface
US6667176B1 (en) 2000-01-11 2003-12-23 Geron Corporation cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells
WO2000035464A1 (fr) 1998-12-16 2000-06-22 Tsentr Embrionalnykh Tkanei 'emcell' Procede permettant de soigner des personnes a l'aide de suspensions cellulaires de tissus embryonnaires
EP1156822B1 (en) 1999-02-24 2006-02-08 Novo Nordisk A/S Iin vitro method for synchronisation of oocyte maturation
US6777231B1 (en) 1999-03-10 2004-08-17 The Regents Of The University Of California Adipose-derived stem cells and lattices
EP1173587A1 (en) 1999-04-23 2002-01-23 Ceptyr, Inc. Dsp-10 dual-specificity map kinase phosphatase
US6355648B1 (en) 1999-05-04 2002-03-12 American Home Products Corporation Thio-oxindole derivatives
US6407101B1 (en) 1999-05-04 2002-06-18 American Home Products Corporation Cyanopyrroles
US6465247B1 (en) 1999-06-29 2002-10-15 The Board Of Trustees Of The Leland Stanford Junior University Mammalian myeloid progenitor cell subsets
US6761883B2 (en) 1999-06-29 2004-07-13 The Board Of Trustees Of The Leland Stanford Junior University Mammalian myeloid progenitor cell subsets
US6872389B1 (en) 1999-07-08 2005-03-29 Rhode Island Hospital Liver stem cell
US6043235A (en) 1999-07-21 2000-03-28 Research Triangle Institute 11β-aryl-17, 17-spirothiolane-substituted steroids
WO2002064748A2 (en) 2001-02-14 2002-08-22 Furcht Leo T Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof
WO2001019379A2 (en) * 1999-09-14 2001-03-22 Children's Medical Center Corporation, The Methods for treating muscular dystrophy with bone marrow cells
CA2386559A1 (en) * 1999-09-14 2001-03-22 The Children's Medical Center Corporation Isolation of muscle-derived stem cells and uses therefor
US20030082155A1 (en) 1999-12-06 2003-05-01 Habener Joel F. Stem cells of the islets of langerhans and their use in treating diabetes mellitus
EP1240518A4 (en) 1999-12-13 2006-05-17 Scripps Research Inst MARKERS FOR THE IDENTIFICATION AND INSULATION OF PRE-GENERIC CELLS OF A AND B PANCREAS ISOLATED CELLS
US6416999B1 (en) 2000-04-07 2002-07-09 Raven Biotechnologies, Inc. Human Müllerian duct-derived epithelial cells and methods of isolation and uses thereof
US6436704B1 (en) 2000-04-10 2002-08-20 Raven Biotechnologies, Inc. Human pancreatic epithelial progenitor cells and methods of isolation and use thereof
UA73119C2 (en) 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
AU2001257236B2 (en) * 2000-04-25 2006-03-09 Mesoblast International Sarl Joint repair using mesenchymal stem cells
NL1017973C2 (nl) 2000-05-10 2002-11-08 Tristem Trading Cyprus Ltd Inrichting.
US6936281B2 (en) 2001-03-21 2005-08-30 University Of South Florida Human mesenchymal progenitor cell
US6921632B2 (en) 2000-08-30 2005-07-26 Maria Biotech Co., Ltd. Human embryonic stem cells derived from frozen-thawed embryo
US20040071665A1 (en) 2000-09-05 2004-04-15 Yong-Fu Xiao Method for therapeutically treating a clinically recognized form of cardiopathology in a living mammal
US6458588B1 (en) 2001-01-31 2002-10-01 The General Hospital Corporation Renal stem cells and uses thereof
US6852532B2 (en) 2001-03-21 2005-02-08 University Of Utah Research Foundation Method of isolating human neuroepithelial precursor cells from human fetal tissue
WO2002079457A1 (en) * 2001-03-29 2002-10-10 Ixion Biotechnology, Inc. Method for transdifferentiation of non-pancreatic stem cells to the pancreatic differentiation pathway
US20030017587A1 (en) 2001-07-18 2003-01-23 Rader William C. Embryonic stem cells, clinical applications and methods for expanding in vitro
DE10139783C1 (de) * 2001-08-14 2003-04-17 Transtissue Technologies Gmbh Zellzusammensetzungen zur Behandlung von Osteoarthrose, sowie Verfahren zu deren Herstellung
EP1443106A4 (en) * 2001-11-06 2005-04-27 Univ Shanghai 2Nd Medical EMBRYONIC STEM CELLS DERIVED FROM SOMATIC CELLS, AND DIFFERENTIATED CELLS THEREOF
US8021876B2 (en) 2001-11-15 2011-09-20 Children's Medical Center Corporation Methods of isolation, expansion and differentiation of fetal stem cells from chorionic villus, amniotic fluid, and placenta and therapeutic uses thereof
EP1456374A4 (en) 2001-11-26 2005-08-17 Advanced Cell Tech Inc METHODS FOR THE PRODUCTION AND USE OF REPROGRAMME HUMAN SOMATIC CELL CORES AND AUTOLOGOUS AND ISOGENIC HUMAN STEM CELLS
CA2479309A1 (en) * 2002-03-15 2003-12-24 Catherine A. Phillips Methods and compositions using cellular asialodeterminants and glycoconjugates for targeting cells to tissues and organs
US20040009589A1 (en) * 2002-03-26 2004-01-15 Shulamit Levenberg Endothelial cells derived from human embryonic stem cells
US7285415B2 (en) * 2002-07-11 2007-10-23 The Regents Of The University Of California Oligodendrocytes derived from human embryonic stem cells for remyelination and treatment of spinal cord injury
MXPA05000972A (es) * 2002-07-25 2005-09-12 Scripps Research Inst Celulas madres hematopoyeticas y metodo de tratamiento de enfermedades oculares neovasculares con las mismas.
MXPA05003829A (es) * 2002-10-11 2005-10-05 Novocell Inc Implantacion de materiales biologicos encapsulados para el tratamiento de enfermedades.
EP1558618A1 (en) 2002-10-11 2005-08-03 Ligand Pharmaceuticals, Inc. 5-(1 ,1 -CYCLOALKYL/ALKENYL)METHYLIDENE 1,2-DIHYDRO- 5H /-CHROMENO[3,4-f ] QUINOLINES AS SELECTIVE PROGESTERONE RECEPTOR MODULATOR COMPOUNDS
EP1551845A1 (en) 2002-10-11 2005-07-13 Ligand Pharmaceuticals, Inc. 5-CYCLOALKENYL 5 i H /i -CHROMENO 3,4-F QUINOLINE DERIV ATIVES AS SELECTIVE PROGESTERONE RECEPTOR MODULATOR COMPOUNDS
US20060252150A1 (en) * 2002-11-08 2006-11-09 Linzhao Cheng Human embryonic stem cell cultures, and compositions and methods for growing same
UA59678A (uk) 2002-11-15 2003-09-15 Національний Медичний Університет Ім. О.О. Богомольця Спосіб лікування ревматоїдного артриту
BRPI0408733A (pt) * 2003-03-12 2006-03-07 Reliance Life Sciences Pvt Ltd derivação de neurÈnios dopaminérgicos terminalmente diferenciados de células tronco embriÈnicas humanas
AU2004269361B2 (en) 2003-08-29 2010-05-20 Wisconsin Alumni Research Foundation Method of in vitro differentiation of neural stem cells, motor neurons and dopamine neurons from primate embryonic stem cells
EP1682150B1 (en) 2003-11-10 2012-12-26 The Scripps Research Institute Compositions and methods for inducing cell dedifferentiation
WO2005052138A1 (en) 2003-11-19 2005-06-09 Wisconsin Alumni Research Foundation Cryopreservation of pluripotent stem cells
UA71388A (uk) 2003-12-26 2004-11-15 Інститут Нейрохірургії Імені Академіка А. П. Ромоданова Академії Медичних Наук України Спосіб отримання збагаченої суспензії стовбурових нейральних клітин
US20050233446A1 (en) * 2003-12-31 2005-10-20 Parsons Xuejun H Defined media for stem cell culture
WO2005080551A2 (en) 2004-02-12 2005-09-01 University Of Newcastle Upon Tyne Stem cells
WO2005099758A2 (en) * 2004-04-17 2005-10-27 The Board Of Trustees The Leland Standford Junior University Injectable bioartificial tissue matrix
EP1812556A4 (en) 2004-10-05 2011-02-02 Univ Georgia NEURONAL PRECURSORS OF FEEDER-FREE HUMAN EMBRYONIC STEM CELL CULTURE
EP2422800A3 (en) 2006-03-07 2013-03-06 Geeta Shroff Compositions comprising human embryonic stem cells and their derivatives, methods of use, and methods of preparation

Also Published As

Publication number Publication date
US20140057250A1 (en) 2014-02-27
US10545135B2 (en) 2020-01-28
EP2422797A2 (en) 2012-02-29
JP2009528834A (ja) 2009-08-13
MX347303B (es) 2017-04-21
US20140051110A1 (en) 2014-02-20
KR20140135263A (ko) 2014-11-25
US9383349B2 (en) 2016-07-05
JP5649786B2 (ja) 2015-01-07
NZ594639A (en) 2013-04-26
EP2422799A3 (en) 2013-03-06
AU2007257594B2 (en) 2012-11-01
EP2422803A2 (en) 2012-02-29
DK1993575T3 (da) 2019-10-14
GEP20135796B (en) 2013-04-10
EP2422794A2 (en) 2012-02-29
MY154677A (en) 2015-07-15
KR20080106332A (ko) 2008-12-04
US20140051164A1 (en) 2014-02-20
EP2422799A2 (en) 2012-02-29
US20130122486A1 (en) 2013-05-16
US8900861B2 (en) 2014-12-02
KR101505382B1 (ko) 2015-03-23
EP2422796A3 (en) 2013-03-13
EP2422798A2 (en) 2012-02-29
EP2422803A3 (en) 2013-03-13
EP2422798A3 (en) 2013-03-06
PH12014501028A1 (en) 2016-02-22
EP2422802A2 (en) 2012-02-29
CA2644922C (en) 2019-07-23
US9488643B2 (en) 2016-11-08
IL193702A0 (en) 2011-08-01
AP2949A (en) 2014-07-31
US20140050706A1 (en) 2014-02-20
JP2014159455A (ja) 2014-09-04
EP2422796A2 (en) 2012-02-29
US9804151B2 (en) 2017-10-31
EA027648B1 (ru) 2017-08-31
BRPI0708576A2 (pt) 2011-05-31
US9134299B2 (en) 2015-09-15
CR10345A (es) 2009-03-30
CN103893211A (zh) 2014-07-02
EP1993575A2 (en) 2008-11-26
EP1993575B1 (en) 2019-07-03
EP2422801A3 (en) 2013-03-06
US20140057350A1 (en) 2014-02-27
WO2007141657A2 (en) 2007-12-13
CA2644922A1 (en) 2007-12-13
CU20080161A7 (es) 2012-11-15
KR101505202B1 (ko) 2015-03-27
US9482660B2 (en) 2016-11-01
EA027648B9 (ru) 2018-01-31
EP2422795A2 (en) 2012-02-29
MA30323B1 (fr) 2009-04-01
CN101420964A (zh) 2009-04-29
MX2008011279A (es) 2008-11-25
NO20084181L (no) 2008-11-26
EP2422795A3 (en) 2013-03-13
AP2008004623A0 (en) 2008-10-31
WO2007141657A3 (en) 2008-04-24
US8592208B2 (en) 2013-11-26
EP2422800A2 (en) 2012-02-29
NZ571127A (en) 2012-01-12
EP2422797A3 (en) 2013-03-20
EP2422800A3 (en) 2013-03-06
EP2422801A2 (en) 2012-02-29
US20190369088A1 (en) 2019-12-05
EP2422802A3 (en) 2013-03-06
EA200801943A1 (ru) 2009-04-28
WO2007141657B1 (en) 2008-07-31
US20130122588A1 (en) 2013-05-16
EP2422794A3 (en) 2013-03-13
IL193702A (en) 2015-02-26
US20090123433A1 (en) 2009-05-14
AU2007257594A1 (en) 2007-12-13

Similar Documents

Publication Publication Date Title
ECSP088799A (es) Composiciones que comprenden células madre embrionarias humanas y sus derivados, métodos de uso y métodos de preparación
JP6918782B2 (ja) 培養培地
BR112014015720A8 (pt) derivados de tieno[3,2-d]pirimidina que têm atividade inibidora de proteinas quinases
NI201200172A (es) Activadores de guanilato ciclasa soluble
BR122020000182B1 (pt) Neurônios dopaminérgicos do mesencéfalo para enxerto
WO2011149762A3 (en) Method of nociceptor differentiation of human embryonic stem cells and uses thereof
BR112014021634A8 (pt) inibidores de serina/treonina quinase,composições que os compreendem, seus usos e seus processos de preparação, e método de inibir a atividade da proteína quinase erk em uma célula
WO2003065999A3 (en) Proliferated cell lines and uses thereof
TNSN08165A1 (en) Agricultural composition
ES2377194T3 (es) Suplemento de medios de cultivo de gametos y de embriones de mamíferos y procedimiento de utilización del mismo
JP2013510127A (ja) トリプトリドの製造方法
KR102121042B1 (ko) 조류의 에그로부터 분리한 세포인 배반엽 전분화능세포, 신경줄기세포, 배아섬유아세포 컨디션드 배지를 유효성분으로 하는 세포 증식, 피부재생 및 주름 개선용 배지 조성물
JP2021520351A (ja) 皮膚を治療するための組成物
BR112012015449A2 (pt) suspensão de monoidrato de calcipotriol, monoidrato de calcipotriol, processo para preparar nanocristais de monoidrato de calcipotriol, e, composição farmacêutica
CU20130075A7 (es) Composición farmacéutica que comprende células madre humanas y sus derivados y métodos de preparación
WO2018215684A1 (es) Medios de cultivo con lisados plaquetarios
UA99813C2 (ru) Композиция человеческих эмбриональных стволовых клеток или их производных, способы применения и способы получения (варианты)
NO20073483L (no) Peptidfraksjoner som fremmer vekst og syntese av onsket produkt(er) inn i celle og/eller vevskultur
BR112016020879A2 (pt) composições, organismos, sistemas e métodos para expressar um produto gênico em plantas
KR20180035763A (ko) 에그 세포 배양액을 유효성분으로 포함하는 인간 줄기세포 성장용 배지 조성물
US11065188B2 (en) Applications and formulations of optimized, modified human embryonic fertility culture media with biguanides and/or functional equivalents
Jayawardana et al. Protease inhibitory activity of some medicinal plants in Sri Lanka
MD191Z5 (ro) Mediu nutritiv pentru cultivarea celulelor de origine animală
Spătaru et al. Assessment of some mitochondrial function based on gene expression in sow oocyte cultured in vitro.
ES2443088A1 (es) Composición y medios de cultivo que comprenden hialurona y un ácido graso esencial poliinsaturado seleccionado de entre ácido linoleico y ácido docosahexaenoico.